Travere Therapeutics (TVTX) Change in Accured Expenses (2011 - 2026)

Travere Therapeutics' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 173.62% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.5 million (up 77.9% YoY) and the FY2025 annual result came in at -$9.7 million, up 44.77% from the prior year.
• Change in Accured Expenses was $1.9 million for Q1 2026 at Travere Therapeutics, up from -$21.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $24.3 million in Q4 2022 and bottomed at -$44.0 million in Q3 2024.
• A 5-year average of $1.3 million and a median of $709000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 184562.5% — and 2024, when it tumbled 397.51%.
• Travere Therapeutics' Change in Accured Expenses stood at $24.3 million in 2022, then retreated by 28.83% to $17.3 million in 2023, then gained by 22.76% to $21.2 million in 2024, then tumbled by 199.86% to -$21.2 million in 2025, then jumped by 109.15% to $1.9 million in 2026.
• Business Quant data shows TVTX's Change in Accured Expenses at $1.9 million in Q1 2026, -$21.2 million in Q4 2025, and $19.7 million in Q3 2025.